The Goal of the Mayo SPORE in Brain Cancer Career Development Program (CDP) will continue into this next grant period - The contribution of knowledgeable and well-trained scientists experienced in multidisciplinary research in, and informed of the public health importance of, primary brain tumors. The premise of this program is that such scientists will advance and significantly impact the nation's brain tumor agenda. The primary objective of the Program is to train young investigators in translational, multidisciplinary brain tumor research. To meet these objectives, the SPORE CDP will have the following components: (1) A stringent candidate selection system; (2) Comprehensive guidance by a scientific group comprised of investigators with expertise in the relevant area of interest and extensive experience as research mentors; and, (3) Prescribed training and education; and, (4) Collaboration with investigators within this SPORE, and with investigators within the other Mayo SPOREs. The CDP builds on its success in the first grant period amplified by Program-specific re-corrections. The CDP will be continue to be immersed in a rich cancer-, neuroscience-, and neurooncology-specific educational environment that includes CDPs of five other Mayo SPORE grants, a Cancer Center Education Portfolio, six NIH-supported cancer-focused T32 training grants, and a Clinical Translational Sciences Award (CTSA). A new Mayo Foundation Office of Research Postgraduate Affairs provides institutional infrastructure to all NIH-funded training and education enterprises including this CDP.
The Mayo SPORE's CDP will provide for integrated training and education to new investigators committed to careers in translational research of primary brain tumors. The format is designed to provide breadth and flexibility to awardees who require additional research knowledge and skills in order to compete for independent extramural grant support and contribute to the Mayo SPORE in Brain Cancer. The CDP will continue as a research experience under the mentorship of established SPORE investigators and supported by SPORE-funded Administrative, Biostatistics, Pathology, Animal, and Clinical Cores.
|Geekiyanage, Hirosha; Galanis, Evanthia (2016) MiR-31 and miR-128 regulates poliovirus receptor-related 4 mediated measles virus infectivity in tumors. Mol Oncol 10:1387-1403|
|Rajani, Karishma; Parrish, Christopher; Kottke, Timothy et al. (2016) Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. Mol Ther 24:166-74|
|Ma, Yufang; Tang, Nan; Thompson, Reid C et al. (2016) InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma. Clin Cancer Res 22:1767-76|
|Hardcastle, Jayson; Mills, Lisa; Malo, Courtney S et al. (2016) Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro Oncol :|
|Vaubel, Rachael A; Chen, Selby G; Raleigh, David R et al. (2016) Meningiomas With Rhabdoid Features Lacking Other Histologic Features of Malignancy: A Study of 44 Cases and Review of the Literature. J Neuropathol Exp Neurol 75:44-52|
|Kurokawa, C; Geekiyanage, H; Allen, C et al. (2016) Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma. J Neurooncol :|
|Zhang, Haoxing; Liu, Hailong; Chen, Yali et al. (2016) A cell cycle-dependent BRCA1-UHRF1 cascade regulates DNA double-strand break repair pathway choice. Nat Commun 7:10201|
|Lescarbeau, Rebecca S; Lei, Liang; Bakken, Katrina K et al. (2016) Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma. Mol Cancer Ther 15:1332-43|
|Kitange, Gaspar J; Mladek, Ann C; Schroeder, Mark A et al. (2016) Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins. Cell Rep 14:2587-98|
|Cockle, Julia V; Rajani, Karishma; Zaidi, Shane et al. (2016) Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. Neuro Oncol 18:518-27|
Showing the most recent 10 out of 220 publications